Cardiology

MOMENTUM data suggest hypercortisolism prevalence reached 43.6% among individuals with resistant hypertension and an eGFR below 45 mL/min/1.73 m².

A Family Heart Database analysis found only 1.1% of US adults have undergone lipoprotein(a) testing.

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

New data presented at ENDO 2026 have indicated substantially lower basal insulin and bolus insulin dose requirements in this population following discharge.

New data from ENDO 2026 have indicated a statistically significant increase in hypotension and related events in adults receiving GLP-1s who are already hypertensive.

Stay updated with the latest healthcare breakthroughs, including data from ADA Scientific Sessions, a new CKM syndrome guideline, and more.

Learn what the first-ever CKM syndrome guideline means for screening, treatment, and the connection between heart disease, kidney disease, diabetes, and obesity.

Stay updated with the latest healthcare breakthroughs, including FDA regulatory decisions, phase 3 data, and new clinical guidelines.

A new substudy of VESALIUS-CV presented at ADA 2026 has confirmed that evolocumab’s cardioprotective effects extend to patients at risk from diabetes.

May 2026 saw substantial FDA decisions, major trial results, guideline updates, and more.

Phase 3 post hoc data linked lorundrostat to lower systolic blood pressure and albuminuria in patients with hypertension and CKD.

FDA accepted a priority review sNDA for mavacamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

FDA De Novo classification clears Cardiosense PCWP Analysis Software to estimate filling pressures in selected adults with HFrEF.

Lilly reports dose-dependent PCSK9 and LDL-C reductions with single-dose VERVE-102 in interim phase 1b hypercholesterolemia data.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Deepak Bhatt, MD, MPH, MBA, discusses his recent presentation at the ASPC 2026 Virtual Imaging Symposium and how plaque imaging can change the MI landscape.

FDA granted priority review to asundexian for secondary prevention after non-cardioembolic ischemic stroke or TIA.

FDA approved baxdrostat as add-on therapy for adults with hypertension not controlled on other medications.

Stay updated with the latest healthcare breakthroughs, including FDA submissions and new cardiology guidelines.

Barry Borlaug, MD, discusses his recent publication collecting existing evidence on HFmrEF to reflect current data regarding treatment and management.

Marc Ruel, MD, MPH, discusses the progress made since in the 11 years since the last guidelines, both in treatment and therapy.

Payam Dehghani, MD, discusses his sub-study of the NACMI registry, following patients with COVID-19 and STEMI who survived to hospital discharge.

Pugazhendhi Vijayaraman, MD, discusses his recent presentation of the final results of LEADR LBBAP, simplifying the lead placement problems faced by earlier models.

Lucas Boersma, MD, PhD, discusses the 1-year results of the Enlighten study, highlighting effective defibrillation, low rate of complications, and high ATP success.